TSS
BGLC icon

Two Sigma Securities’s BioNexus Gene Lab BGLC Stock Holding History

Two Sigma Securities’s Portfolio BGLC Stock Details BGLC Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q1 		– Sell
-1,492
Closed -$7.91K – 2984
2023
Q4 		$7.91K Sell
1,492
-807
-35% -$4.59K ﹤0.01% 2849
2023
Q3 		$20K Buy
+2,299
New +$37.4K ﹤0.01% 2572

Other funds holding BGLC

VF
Virtu Financial New York $2.41B AUM 48.35% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
HF
HRT Financial New York $40.1B AUM 58.22% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return

Two Sigma Securities's BGLC Position: Q1 2024 in Review

Two Sigma Securities sold out of BioNexus Gene Lab (BGLC) in Q1 2024, closing a stake of 1,492 shares — an estimated $7.91K sold.

Two Sigma Securities first reported a position in BGLC in Q3 2023 and held it in 2 quarters. The position peaked at $20K in Q3 2023. 4 funds tracked by Wall St. Rank hold BGLC as of Q1 2024.

  • Two Sigma Securities reported no remaining BioNexus Gene Lab position as of Q1 2024 after selling out during the quarter.
  • Two Sigma Securities sold 1,492 BioNexus Gene Lab shares in Q1 2024, an estimated $7.91K.
  • Two Sigma Securities first reported a position in BioNexus Gene Lab in Q3 2023 and held it in 2 quarters.
  • Two Sigma Securities's BioNexus Gene Lab position peaked at $20K in Q3 2023.
  • 4 funds tracked by Wall St. Rank held BioNexus Gene Lab as of Q1 2024.

Based on Two Sigma Securities's 13F filing for Q1 2024, filed 15 May 2024.